Autonomix Medical Reports $2.7 Million Net Loss and Decreased Operating Expenses for Q2 2026

Autonomix Medical, Inc. reported its financial results for the three months ending June 30, 2026, revealing a net loss of $2.7 million, a decrease from a loss of $3.3 million during the same period in 2025. The company did not generate any revenue in either quarter. Total operating expenses for the recent quarter were $2.77 million, down 19% from $3.42 million in the prior year, primarily due to reduced general and administrative costs, which fell by 31% to $1.26 million. Research and development expenses also decreased slightly by 5% to $1.52 million.

The company’s cash and cash equivalents stood at $3.46 million as of June 30, 2026, a significant decline from $7.00 million at the end of the previous quarter. Autonomix's total assets decreased to $3.98 million from $7.60 million, while total liabilities were reduced to $0.82 million from $1.71 million. The accumulated deficit increased to $69.82 million, reflecting ongoing operational losses since the company's inception.

In terms of strategic developments, Autonomix has made notable progress in its clinical studies and product development. The company is focused on advancing its technology for treating disorders of the nervous system, particularly pain associated with pancreatic cancer. Following initial positive findings from a proof-of-concept study, the company paused enrollment to refine its clinical approach due to variability in outcomes. Additionally, on July 9, 2026, Autonomix regained compliance with Nasdaq's minimum bid price requirement, which had previously been a concern.

Operationally, the company has not reported any significant changes in customer counts or user statistics, as it remains in the development stage without product revenue. The company’s employee headcount remains stable, with ongoing efforts to enhance its management team and financial reporting capabilities. Autonomix is actively seeking additional capital, estimating a need of $25 to $30 million to fund operations through the commercialization of its first product indication. The company acknowledges that failure to secure this funding could necessitate scaling back operations.

Looking ahead, Autonomix's management has expressed the need for additional financing to support its business plan, including obtaining regulatory clearance for its products. The company is aware of the risks associated with its early-stage status and the challenges of raising capital in a competitive environment. The outlook remains cautious, with management emphasizing the importance of securing sufficient funds to meet operational obligations and achieve its strategic objectives.